[
  {
    "ts": null,
    "headline": "Analysts Turn More Constructive on Johnson & Johnson (JNJ) Heading Into 2026",
    "summary": "Johnson & Johnson (NYSE:JNJ) is among the most profitable US stocks to buy. On January 9, Lee Hambright at Bernstein raised the price target on Johnson & Johnson (NYSE:JNJ) to $208 from $193 and kept the ‘Market Perform’ rating unchanged, according to TheFly. The firm noted that U.S. healthcare stocks have shown improved performance over […]",
    "url": "https://finnhub.io/api/news?id=e1429eb39fb90cd6767570b8ea50c846a487f6dbdb319965ea2ddcc875695b57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768591025,
      "headline": "Analysts Turn More Constructive on Johnson & Johnson (JNJ) Heading Into 2026",
      "id": 138155342,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is among the most profitable US stocks to buy. On January 9, Lee Hambright at Bernstein raised the price target on Johnson & Johnson (NYSE:JNJ) to $208 from $193 and kept the ‘Market Perform’ rating unchanged, according to TheFly. The firm noted that U.S. healthcare stocks have shown improved performance over […]",
      "url": "https://finnhub.io/api/news?id=e1429eb39fb90cd6767570b8ea50c846a487f6dbdb319965ea2ddcc875695b57"
    }
  },
  {
    "ts": null,
    "headline": "J&J’s Caplyta doubles remission rate in MDD patients",
    "summary": "J&J presented the new analysis from three Phase III trials of Caplyta in MDD.",
    "url": "https://finnhub.io/api/news?id=2e41d8a42103430a3176c9b0cab7f41bd380b7cef43f685db72cb891c80cdfe4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768585432,
      "headline": "J&J’s Caplyta doubles remission rate in MDD patients",
      "id": 138155343,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "J&J presented the new analysis from three Phase III trials of Caplyta in MDD.",
      "url": "https://finnhub.io/api/news?id=2e41d8a42103430a3176c9b0cab7f41bd380b7cef43f685db72cb891c80cdfe4"
    }
  },
  {
    "ts": null,
    "headline": "Earnings Data Deluge",
    "summary": "Earnings Data Deluge",
    "url": "https://finnhub.io/api/news?id=c1c92d1bdc2b7e3c904121299fc334fb86eda2cd40fbaac18cd52465458e30cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768581000,
      "headline": "Earnings Data Deluge",
      "id": 138153995,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Earnings Data Deluge",
      "url": "https://finnhub.io/api/news?id=c1c92d1bdc2b7e3c904121299fc334fb86eda2cd40fbaac18cd52465458e30cb"
    }
  },
  {
    "ts": null,
    "headline": "Pre-Markets Lower on Bank Earnings, Ahead of Bigger Week",
    "summary": "PNC Financial, MTB Bank, State Street and Regions are all out with fresh earnings reports this morning.",
    "url": "https://finnhub.io/api/news?id=43a5a0035d98390b0f2a1dd8562edec7ff0afc86eb1aa1f045e56d5e29065469",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768577280,
      "headline": "Pre-Markets Lower on Bank Earnings, Ahead of Bigger Week",
      "id": 138153996,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "PNC Financial, MTB Bank, State Street and Regions are all out with fresh earnings reports this morning.",
      "url": "https://finnhub.io/api/news?id=43a5a0035d98390b0f2a1dd8562edec7ff0afc86eb1aa1f045e56d5e29065469"
    }
  },
  {
    "ts": null,
    "headline": "Cell and Gene Therapy Investment Trends Strategic Intelligence Report 2025-2031: Yescarta from Gilead Sciences and Zolgensma from Novartis Generated $1.5 Billion and $1.2 Billion in 2024 Sales",
    "summary": "Cell and gene therapies present promising opportunities, especially in oncology, blood disorders, and neurology. Investors prioritize scalable platforms and clear regulatory paths. Focus has shifted to faster development, manufacturing efficiency, and addressing prevalent diseases. Partnerships and innovation drive market growth.Dublin, Jan. 16, 2026 (GLOBE NEWSWIRE) -- The \"Strategic Intelligence: Cell and Gene Therapy Investment Trends\" report has been added to ResearchAndMarkets.com's offerin",
    "url": "https://finnhub.io/api/news?id=889a66bfb7b7984695bd2bcc31b97b3e006e3c4a8c45162e9dd25e57304465b9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768558980,
      "headline": "Cell and Gene Therapy Investment Trends Strategic Intelligence Report 2025-2031: Yescarta from Gilead Sciences and Zolgensma from Novartis Generated $1.5 Billion and $1.2 Billion in 2024 Sales",
      "id": 138150984,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Cell and gene therapies present promising opportunities, especially in oncology, blood disorders, and neurology. Investors prioritize scalable platforms and clear regulatory paths. Focus has shifted to faster development, manufacturing efficiency, and addressing prevalent diseases. Partnerships and innovation drive market growth.Dublin, Jan. 16, 2026 (GLOBE NEWSWIRE) -- The \"Strategic Intelligence: Cell and Gene Therapy Investment Trends\" report has been added to ResearchAndMarkets.com's offerin",
      "url": "https://finnhub.io/api/news?id=889a66bfb7b7984695bd2bcc31b97b3e006e3c4a8c45162e9dd25e57304465b9"
    }
  },
  {
    "ts": null,
    "headline": "Why ORIC Pharmaceuticals (ORIC) Is Up 36.3% After New Cancer Data And Analyst Buzz",
    "summary": "ORIC Pharmaceuticals recently drew investor attention with positive analyst commentary, new clinical data on its lead oncology candidates, and a high-profile presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Promising efficacy signals for ORIC-944 in metastatic castration-resistant prostate cancer and a collaboration evaluating enozertinib with Johnson & Johnson’s amivantamab have strengthened confidence in the company’s late-stage cancer pipeline. We’ll now...",
    "url": "https://finnhub.io/api/news?id=fe76aba0db20107ab024bef02a10e00697a5516e7abf11680ab640d04ccbecd9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768533353,
      "headline": "Why ORIC Pharmaceuticals (ORIC) Is Up 36.3% After New Cancer Data And Analyst Buzz",
      "id": 138147457,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "ORIC Pharmaceuticals recently drew investor attention with positive analyst commentary, new clinical data on its lead oncology candidates, and a high-profile presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Promising efficacy signals for ORIC-944 in metastatic castration-resistant prostate cancer and a collaboration evaluating enozertinib with Johnson & Johnson’s amivantamab have strengthened confidence in the company’s late-stage cancer pipeline. We’ll now...",
      "url": "https://finnhub.io/api/news?id=fe76aba0db20107ab024bef02a10e00697a5516e7abf11680ab640d04ccbecd9"
    }
  }
]